Abstract 1160P
Background
Nivolumab obtained marketing authorization in advanced melanoma (AM) with weight-adjusted (WA) dose administration (3 mg/kg/2 weeks) 1. Based on modeling studies (no clinical data), EMA advised in 2018 that nivolumab should be administered in flat dose regimen (240 mg/2 weeks or 480 mg/4 weeks) 2 3. The aim of the FLATIMEL study was to compare clinical outcomes of AM patients treated with both nivolumab dose calculation methods.
Methods
AM patients were prospectively included in the national multicenter MelBase database since 2013 (NCT02828202). Patients treated by nivolumab monotherapy in first line enrolled in MelBase were included in our study. We compared safety and efficacy of nivolumab in 2 groups of patients treated by flat or WA dose. The primary endpoint was the incidence of immune-related adverse events (irAEs) of grade ≥ 3. Secondary endpoints were incidence of irAEs of any grade, overall survival (OS) and progression free survival (PFS). Inverse probability of treatment weighting was used to balance groups on their baseline characteristics.
Results
Between June 2015 and January 2022, 546 patients followed in MelBase were included in this study: 252 in the flat dose group and 294 in the WA group. Patients with metastatic organs ≥ 3 (p<0.0001), brain metastasis (p=0.0005) or M1c AJCC (7th edition) tumor stage (p=0.001) were more frequent in the WA group. After weighting, no difference between both groups was observed for irAEs grade ≥ 3 (n=65, 12%), (p= 0.51), whereas irAEs of any grade (n=314, 57.5%) were more frequent in the flat dose group (p=0.044), especially muco-cutaneous and endocrine toxicities. Median OS was 32.3 and 20.6 months in flat dose and WA group respectively (p= 0.004), and median PFS was 3.5 and 2.8 months, respectively (p= 0.003).
Conclusions
There was no difference in the incidence of severe irAEs between AM patients treated by WA or flat dose of Nivolumab. Survival results were superior in the flat dose group, which may be explained by a temporal bias. Cost effectiveness studies are necessary.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
MELBASE database.
Funding
INCa, Roche, BMS, Novartis, MSD, Amgen.
Disclosure
L. Mortier: Financial Interests, Personal, Advisory Board: BMS, MSD, Pierre Fabre, Novartis, Sanofi. H. Montaudie: Financial Interests, Personal, Research Funding: BMS, Merck, MSD, Novartis, Pierre Fabre, Leo pharma, Checkpoint Therapeutic, Huyaboiscience, Incyte, Nektar Pharmaceutical, Regeneron, Replimune; Financial Interests, Personal, Funding: BMS, Merck Serono, MSD Novartis, Pierre Fabre; Financial Interests, Institutional, Advisory Board: BMS, Leo Pharma. C. Pages: Financial Interests, Personal, Advisory Board: BMS. C. Lebbe: Financial Interests, Personal, Funding: Roche, BMS, Novartis, Amgen, MSD, Pierre Fabre, Pfizer, Incyte; Financial Interests, Personal, Advisory Role: BMS, MSD, Novartis, Amgen, Roche, Merck Serono, Sanofi, Pierre Fabre; Financial Interests, Personal, Invited Speaker: Roche, BMS, Novartis, Amgen, MSD; Financial Interests, Institutional, Research Funding: Roche, BMS, Novartis, Amgen, MSD; Financial Interests, Personal, Advisory Board: Avantis Medical Systems, InflaRx, Sanofi, BMS, MSD, Pierre Fabre, Novartis, Jazz Pharmaceuticals; Financial Interests, Personal, Other: BMS, MSD, Novartis, Sanofi, Pierre Fabre. All other authors have declared no conflicts of interest.
Resources from the same session
1149P - Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment
Presenter: Lisanne Zijlker
Session: Poster session 13
1150P - Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Presenter: Bernardo Rapoport
Session: Poster session 13
1151P - Characteristics and treatment outcomes in cutaneous adnexal carcinomas
Presenter: Adam Rock
Session: Poster session 13
1152P - Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Presenter: Fernanda Costa Svedman
Session: Poster session 13
1153P - Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
Presenter: Minke Lucas
Session: Poster session 13
1154P - Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Presenter: Daan van Dorst
Session: Poster session 13
1155P - Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Presenter: Roslyn Francis
Session: Poster session 13
1156P - Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Presenter: Eva Ellebæk
Session: Poster session 13
1157P - Corticosteroids and second-line immunosuppressants for immune-related adverse events and melanoma survival
Presenter: Rik Verheijden
Session: Poster session 13
1158P - Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Presenter: Ha Mo Linh Le
Session: Poster session 13